Inversion Deals – PharmaLive

Pfizer Boss Says No to Tax Inversions

Business, Deals, Deals, Health, Inversion Deals, M&A, M&A, Stocks, Stocks, Tax Inversions, U.S. Treasury Department

Now that Pfizer has had two major deals dashed by government resistance, Pfizer CEO Ian Read says he will not be doing any more tax inversions.

June 3, 2016/by BioSpace

Investors Assure Pfizer’s Ian Read: We Have Your Back

Business, Health, Inversion Deals, M&A, M&A, Tax Inversions

Investors have indicated they support Pfizer CEO Ian Read and his strategies despite a second failed attempt at a big tax inversion deal.

April 8, 2016/by BioSpace

Biotech 2016: Now Starts the Hangover

Analysts, Approvals, Approvals, Biotech, Biotechnology, Business, Health, Inversion Deals, Launches, Launches, M&A, M&A, Nasdaq Biotech Index, Product Launches, Stock Markets, Stocks, Stocks

January 27, 2016By Karl Thiel for BioSpace.com Not that you need to be reminded of this, but… For the stock market, this has been the worst kickoff ever to […]

January 27, 2016/by BioSpace

After three weeks of speculation New York-based Pfizer Inc. (PFE) announced today that it was merging with Dublin, Ireland-based Allergan plc (AGN). Board members for both companies unanimously voted Sunday […]

November 23, 2015/by BioSpace

Pfizer-Allergan Talks About a $3-4.5 Billion Break-Up Fee, Making Allergan the Buyer Instead

Break-Up Fees, Business, Deals, Deals, Expirations, Generics, Inversion Deals, M&A, M&A, Patents, Politics, R&D, Tax Rates, Tax Savings, Therapeutics

Yesterday’s announcement by the U.S. Treasury Department of rules changes to make tax inversions more difficult, might stop the pending Pfizer Inc. (PFE)-Allergan, Inc. (AGN) deal, but insiders are indicating […]

November 20, 2015/by BioSpace